Clinical effects and pharmacokinetics of nebulized lidocaine in healthy horses

Minuto, Jillian; Bedenice, Daniela; Ceresia, Michelle L.; Zaghloul, Iman; Böhlke, Mark; Mazan, Melissa R.

doi:10.3389/fvets.2022.984108

Cited by 4 publications

(1 citation statement)

References 55 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This agrees with previous reports describing the pharmacokinetics of lidocaine HCl in horses. 6 , 9 In the present study, the mean terminal half-life of lidocaine (3.78 h), determined using NCA, was longer than that reported by Soma and colleagues (0.18 h). 6 However, it should be noted that the analytical method utilized in the current study was more sensitive as compared to the previous study.…”

Section: Discussioncontrasting

confidence: 58%

Pharmacokinetics and metabolism of lidocaine HCl 2% with epinephrine in horses following a palmar digital nerve block

Knych,

Katzman,

McKemie

et al. 2023

BMC Vet Res

View full text Add to dashboard Cite

Background Lidocaine is a local anesthetic that is sometimes administered in combination with epinephrine. The addition of epinephrine increases the time lidocaine remains at the site of administration, thus prolonging the duration of effect. Due to their potential to prevent the visual detection of lameness, the administration of local anesthetics is strictly regulated in performance and racehorses. Recent reports of positive regulatory findings for lidocaine in racehorses suggests a better understanding of the behavior of this drug is warranted. The objective of the current study was to describe serum and urine concentrations and the pharmacokinetics of lidocaine and its primary metabolites following administration in combination with epinephrine, as a palmar digital nerve block in horses. Twelve horses received a single administration of 1 mL of 2% lidocaine HCl (20 mg/horse) with epinephrine 1:100,000, over the palmar digital nerve. Blood samples were collected up to 30 h and urine samples up to 48 h post administration. Lidocaine and metabolite concentrations were determined by liquid chromatography- mass spectrometry and pharmacokinetic (non-compartmental and compartmental) analysis was performed. Results Serum concentrations of lidocaine and 3-hydroxylidocaine were above the LOQ of the assay at 30 h post administration and monoethylglycinexylidide (MEGX) and glycinexylidide (GX) were below detectable levels by 24 and 48 h, respectively. In urine, lidocaine, MEGX and GX were all non-detectable by 48 h post administration while 3-hydroxylidocaine was above LOQ at 48 h post administration. The time of maximal concentration for lidocaine was 0.26 h (median) and the terminal half-life was 3.78 h (mean). The rate of absorption (Ka) was 1.92 1/h and the rate of elimination (Kel) was 2.21 1/h. Conclusions Compared to previous reports, the terminal half-life and subsequent detection time observed following administration of lidocaine in combination with epinephrine is prolonged. This is likely due to a decrease in systemic uptake of lidocaine because of epinephrine induced vasoconstriction. Results of the current study suggest it is prudent to use an extended withdrawal time when administering local anesthetics in combination with epinephrine to performance horses.

show abstract

Section: Discussioncontrasting

confidence: 58%